公开(公告)号：KR101580681B1

公开(公告)日：2015-12-29

申请号：KR1020130021769

申请日：2013-02-28

Applicant: 재단법인 의약바이오컨버젼스연구단

Inventor： 김성훈 ,  박민철

IPC: C12N5/071 ,  C12N9/00 ,  A61P35/00

Abstract: 본발명은글라이실-tRNA 합성효소(GRS)를포함하는마이크로베지클의제조방법에관한것으로, 더욱상세하게는글라이실-tRNA 합성효소를포함하는마이크로베지클의제조방법및 상기제조방법으로제조된마이크로베지클과이의용도에관한것이다. 본발명의제조방법으로제조한 GRS를포함하는마이크로베지클은암을치료하는데효과적이다.

公开(公告)号：KR1020130118612A

公开(公告)日：2013-10-30

申请号：KR1020120041623

申请日：2012-04-20

Applicant: 재단법인 의약바이오컨버젼스연구단

Inventor： 김성훈 ,  권남훈 ,  이희숙 ,  오영선 ,  김대규

IPC: C07D213/75 ,  C07D215/38 ,  A61K31/435 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4706

CPC classification number: C07D215/38 ,  A61K31/435 ,  C07D213/75 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4706

Abstract: PURPOSE: A novel aminopyridine derivative is provided to suppress the activity of AIMP2-DX2 which is a new target of an anticancer agent and to effectively induce apoptosis of cancer cells, thereby effectively preventing and treating cancer. CONSTITUTION: An aminopyridine derivative of chemical formula 1 or a pharmaceutically acceptable salt thereof is provided. A pharmaceutical composition for preventing or treating cancer contains the aminopyridine derivative of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The derivative is selected among ethyl 3-[(5-chloropyridine-2-yl)amino]-2-methyl-3-oxopropanoate, ethyl 3-[(6-methylpyridine-2-yl)amino]-3-oxopropanoate, ethyl 3-oxo-3-(quinoline-3-ylamino) propanoate, ethyl 3-[(3,6-dimethylpyridine-2-yl)amino]-3-oxopropanoate, ethyl 3-[(4-hydroxypyridine-2-yl)amino]-3-oxopropanoate, ethyl 2-methyl-3-oxo-3-(quinoline-3-ylamino) propanoate, ethyl 2-methyl-3-[(6-methylpyridine-2-yl)amino]-3-oxopropanoate, and ethyl 3-[(5-chloropyridine-2-yl)amino]-3-oxopropanoate.

Abstract translation: 目的：提供一种新的氨基吡啶衍生物，以抑制作为抗癌剂新靶标的AIMP2-DX2的活性，有效诱导癌细胞凋亡，从而有效预防和治疗癌症。 构成：提供化学式1的氨基吡啶衍生物或其药学上可接受的盐。 用于预防或治疗癌症的药物组合物含有化学式1的氨基吡啶衍生物或其药学上可接受的盐作为活性成分。 该衍生物选自3 - [（5-氯吡啶-2-基）氨基] -2-甲基-3-氧代丙酸乙酯，3 - [（6-甲基吡啶-2-基）氨基] -3-氧代丙酸乙酯，乙基 3-（3-喹啉-3-基氨基）丙酸乙酯，3 - [（3,6-二甲基吡啶-2-基）氨基] -3-氧代丙酸乙酯，3 - [（4-羟基吡啶-2-基） 氨基] -3-氧代丙酸乙酯，2-甲基-3-氧代-3-（喹啉-3-基氨基）丙酸乙酯，2-甲基-3 - [（6-甲基吡啶-2-基）氨基] -3-氧代丙酸乙酯 ，和3 - [（5-氯吡啶-2-基）氨基] -3-氧代丙酸乙酯。

公开(公告)号：KR1020130032286A

公开(公告)日：2013-04-01

申请号：KR1020120105694

申请日：2012-09-24

Applicant: 재단법인 의약바이오컨버젼스연구단

Inventor： 김성훈 ,  한정민

IPC: C12N15/113 ,  G01N33/15 ,  C12N9/00 ,  G01N33/68

CPC classification number: G01N33/573 ,  C12N15/1137 ,  C12N2310/14 ,  C12Y601/01004 ,  G01N33/574 ,  G01N2800/044

Abstract: PURPOSE: A method for screening a therapeutic agent for mTORC1(mammalian target of rapamycin complex 1)-induced diseases is provided to control cell size, and to develop a novel therapeutic agent for treating cancer. CONSTITUTION: A method for screening a therapeutic agent for preventing and treating mTORC1-mediated diseases comprises: a step of contacting LRS(leucyl tRNA synthetase), RagD, and a test agent under the presence or absence of the therapeutic agent; a step of comparing the LRS and RagD binding under the presence or absence of the therapeutic agent; and a step of measuring binding change.

Abstract translation: 目的：提供用于筛选mTORC1（雷帕霉素复合物1的哺乳动物靶）诱导的疾病的治疗剂的方法以控制细胞大小，并开发用于治疗癌症的新型治疗剂。 构成：用于筛选预防和治疗mTORC1介导的疾病的治疗剂的方法包括：在存在或不存在治疗剂的情况下使LRS（亮氨酰tRNA合成酶），RagD和试验剂接触的步骤; 在存在或不存在治疗剂的情况下比较LRS和RagD结合的步骤; 和测量绑定变化的步骤。

公开(公告)号：KR1020130016134A

公开(公告)日：2013-02-14

申请号：KR1020120085685

申请日：2012-08-06

Applicant: 재단법인 의약바이오컨버젼스연구단

Inventor： 김성훈 ,  이희숙 ,  오영선 ,  김대규

IPC: C07C233/07 ,  C07C233/09 ,  C07C233/15 ,  C07C233/25 ,  C07C233/27 ,  A61K31/167

CPC classification number: C07C235/74 ,  A61K31/167 ,  A61P35/00 ,  C07C233/04 ,  C07C233/07 ,  C07C233/09 ,  C07C233/15 ,  C07C233/25 ,  C07C233/27 ,  C07C235/76 ,  C07C2603/24

Abstract: PURPOSE: An aniline derivative is provided to effectively derive the death of cancer cells by reducing the activity of AIMP2-DX2 which is a target for a new anticancer drug. CONSTITUTION: An aniline derivative is indicated in chemical formula 1. In the chemical formula 1: each of R1-R5 is selected from hydrogen, C1-C4 linear, branched or cyclic alkyl, halogen, alkoxy, and hydroxy; R6 is -CO-CH=CH-COR7 or -CO-CHR9-COR8; R7 is a hydroxy or a functional group indicated in chemical formula 1-a; R8 is a C1-6 alkoxy or a functional group indicated in chemical formula 1-b; R9 is hydrogen or a C1-6 alkyl; and each of R10-R14 is selected from hydrogen, methyl, halogen, and methoxy.

Abstract translation: 目的：提供苯胺衍生物，通过降低作为新抗癌药物靶标的AIMP2-DX2的活性来有效地导致癌细胞的死亡。 化学式1表示苯胺衍生物：化学式1：R1-R5各自选自氢，C1-C4直链，支链或环状烷基，卤素，烷氧基和羟基; R6是-CO-CH = CH-COR7或-CO-CHR9-COR8; R7是化学式1-a所示的羟基或官能团; R8是C1-6烷氧基或化学式1-b表示的官能团; R9为氢或C1-6烷基; R 10 -R 14选自氢，甲基，卤素和甲氧基。

公开(公告)号：KR1020110049364A

公开(公告)日：2011-05-12

申请号：KR1020090106350

申请日：2009-11-05

Applicant: 재단법인 의약바이오컨버젼스연구단

Inventor： 김성훈 ,  최진우 ,  이진영 ,  김대규 ,  한균희 ,  양지선 ,  이철호

IPC: A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61P35/00

CPC classification number: A61K31/4184 ,  A61K31/423 ,  A61K31/428

Abstract: PURPOSE: A composition containing benzoheterocycle derivatives for preventing and treating cancer is provided to suppress cancer or tumor by inhibiting interaction of KRS and 67LR. CONSTITUTION: A pharmaceutical composition for preventing or treating cancer contains benzoheterocycle derivative of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In chemical formula 1, A is O, NH, or S; X is C or N; and R1 is hydrogen, non-substituted or halogen-substituted alkyl, alkoxy, halogen, nitro, or amine. The cancer is colon cancer, lung cancer, liver cancer, gastric cancer, bladder cancer, uterine cancer, brain cancer, or melanoma.

Abstract translation: 目的：提供含有用于预防和治疗癌症的苯并杂环衍生物的组合物，通过抑制KRS和67LR的相互作用来抑制癌症或肿瘤。 构成：用于预防或治疗癌症的药物组合物含有化学式1的苯并杂环衍生物或其药学上可接受的盐作为活性成分。 在化学式1中，A是O，NH或S; X为C或N; 并且R 1是氢，未取代或卤素取代的烷基，烷氧基，卤素，硝基或胺。 癌症是结肠癌，肺癌，肝癌，胃癌，膀胱癌，子宫癌，脑癌或黑素瘤。

公开(公告)号：KR102133929B1

公开(公告)日：2020-07-14

申请号：KR1020180069146

申请日：2018-06-15

Applicant: 재단법인 의약바이오컨버젼스연구단

Inventor： 권남훈 ,  김성훈 ,  이진영 ,  김건호

IPC: A61K48/00 ,  A61K31/713 ,  A61K39/395 ,  G01N33/50

公开(公告)号：KR101935372B1

公开(公告)日：2019-01-04

申请号：KR1020150075073

申请日：2015-05-28

Applicant: 재단법인 의약바이오컨버젼스연구단

Inventor： 김성훈 ,  박민철

IPC: C12N9/00 ,  A61K9/51 ,  C12P21/00

公开(公告)号：KR101917677B1

公开(公告)日：2018-11-12

申请号：KR1020170068520

申请日：2017-06-01

Applicant: 재단법인 의약바이오컨버젼스연구단 ,  연세대학교 산학협력단

Inventor： 이동기 ,  장윤수 ,  김은영 ,  장성일 ,  김성훈 ,  권남훈

IPC: C12Q1/68 ,  G01N33/574

Abstract: 본발명은폐암의예후예측용바이오마커로서메티오닐-티알엔에이합성효소(MRS)의유용성에관한것으로, 보다상세하게는폐암환자의예후예측에필요한정보를제공하기위한마커로서메티오닐-티알엔에이합성효소(methionyl-tRNA synthetase, MRS) 및이의용도에관한것이다. 본발명에따른폐암예후예측용마커를이용하면예후가양호하지않은환자와양호한환자를정확하면서도신속하게구분할수 있고, 이를통해암의예후를조기에판단하여적절한치료방법을선택및 적용함으로써환자의생존율을높이고재발율을낮출수 있다.

公开(公告)号：KR101888185B1

公开(公告)日：2018-08-13

申请号：KR1020130167851

申请日：2013-12-30

Applicant: 재단법인 의약바이오컨버젼스연구단 ,  이화여자대학교 산학협력단

Inventor： 김성훈 ,  최연식 ,  심현보 ,  이남주 ,  박민화

IPC: C07K16/18 ,  C07K16/40 ,  C12N15/13 ,  G01N33/574

Abstract: 본발명은 AIMP1/p43(ARS-interacting multifunctional protein 1)에선택적으로결합하는항 AIMP1/p43 항체에관한것으로보다구체적으로는인간 AIMP1/p43에결합하는항체또는그 단편, 이의생산방법및 이를포함하는암 치료용약학적조성물또는암 및염증성질환진단용조성물에관한것이다. 본발명의항체또는그 단편은인간 AIMP1/p43에특이적으로결합하며, 동일한 ARS family를포함한다른단백질과교차반응성이없어 AIMP1/p43 검출및 억제가가능하므로 AIMP1/p43 검출및 AIMP1/p43가관련된질환인암 치료또는암 및염증성질환진단목적으로사용될수 있다.

公开(公告)号：KR101878974B1

公开(公告)日：2018-07-16

申请号：KR1020160022480

申请日：2016-02-25

Applicant: 재단법인 의약바이오컨버젼스연구단

Inventor： 김성훈 ,  박민철 ,  피터찰스고흐너

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: C12Q1/68 ,  G01N33/574

Abstract: 본발명은신장암진단용조성물과진단마커검출방법에관한것으로, 보다상세하게는, GRS(glycyl-tRNA synthetase), HRS(histidyl-tRNA synthetase) 및 AIMP1(aminoacyl-tRNA synthetase complex-interacting multifunctional Protein 1)으로이루어진군에서선택된하나이상의 mRNA 또는이의단백질의발현수준을측정하는제제를포함하는신장암진단용조성물및 신장암진단에필요한정보를제공하기위하여피검체로부터수득한시료로부터상기마커를검출하는방법에관한것이다. GRS, HRS 및 AIMP1으로이루어진본 발명의신장암진단마커는신장암환자의혈청에서정상대조군과비교해그 발현수준이증가해있다. 따라서, GRS, HRS 및 AIMP1로이루어진군에서선택된하나이상의마커의발현수준을측정함으로써신장암유무를정확하고신속하게판단할수 있다.